NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD
Taking everything into account, MRUS scores 4 out of 10 in our fundamental rating. MRUS was compared to 567 industry peers in the Biotechnology industry. While MRUS has a great health rating, there are worries on its profitability. While showing a medium growth rate, MRUS is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.51% | ||
ROE | -33.23% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 11.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 6.54 | ||
Quick Ratio | 6.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
44.19
-1.26 (-2.77%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 84.5 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.71 | ||
P/tB | 4.72 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.51% | ||
ROE | -33.23% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 74.06% | ||
Cap/Sales | 5.06% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 6.54 | ||
Quick Ratio | 6.54 | ||
Altman-Z | 11.89 |